ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "The Coast 2 Coast Challenge benefiting the SYNGAP1 #ProMMiS for Clinical Excellence is critical. #S10e152"
Episode Synopsis
Tuesday, October 22, 2024
First Principles
Genetic disease means that gene broken since conception.
Novel medicines are possible ways to fix the gene - Genetic Therapies (ASO &/or AAV), this is recent, before now, kids with these diseases were a “go home and love them” situation.
These are delivered via spinal tap or directly to the brain in leading medical centers.
First though, regulators must approve.
Our job
Develop medicines or get industry to - This is happening see Pipeline
Get regulators to approve trials
Get medical centers up to speed on SYNGAP1-Related Disorders (SRD)
What we are building on
CHOP ENDD funded externally (see #S10e92) and replicating what was built for STXBP1, check last week’s webinar https://curesyngap1.org/resources/webinars/93-endd-chop-2024-syngap1/
Rare-X platform for PRO collection
Regulatory pathway being made clearer every day by Stoke (Dravet), Praxis (SCN2A), Ionis (many) all of whom are working on SYNGAP1 as well.
What we are asking for
We need to raise at least $500k (3rd site), preferably $1.13M (ProMMiS)
Make your largest gift ever to SRF
Fundraise with friends and family
ACES is now ProMMiS, who knew ACE meant Adverse Childhood Event, not us.
Key slides: S1 Path to Treatment | 2024 (09.27.24)
1. Why Now? Why is it time to go from bench to bedside (research to clinical)?
At least 10 companies on our pipeline not to mention multiple small molecule efforts
We have limited resources – so the focus has to transition, clinical funding first.
CHOP Gift is 1 year down…
2. Why NHS?Understand SYNGAP1 better, go beyond Vlaskamp 2019 and Wiltrout 2024, see #S10e105
FYI at CHOP, as I shared in #S10e151, at year 1, we are at – 86 (Visits) + 10 (new scheduled) + 19 (2nd) + 4 (3rd) + 22 (follow up)
Learn what to measure in clinical trials for SRD, remember our seizures are challenging
Ideally we develop a Synthetic Control Arm if we use GCP
Why top shelf? We need institutions the FDA will take seriously and our children are very complex requiring experienced clinicians.
3. Why Multidisciplinary.
Neuro, Psych, Genetics, PT, ST, OT, GI, Sleep, ENT, Ortho.
Beyond the sheer burden of getting our kids out and about for multiple appointments the coordination by a parent is almost impossible.
4. Why Multisite/3 sites?Replicable/scalable required by regulators
Accessibility (not primary reason)
Establish more locations where trials will be managed
Laying a foundation for a national self-sustaining network
3 is the minimum, look at STARR or Angelman, both had/ve 4.
5. How and why so fast?
Because we can. Time is Brain.
Following a well trodden path
SMA, Rett, Angelman, Dravet, but we are moving FASTER.
6. Does the industry really care?
We are next there are so so many behind us, eager to take the resources we have access to today.
Market size (Per our Census 425 US/1500 global is tip of iceberg)
Multiple players reassuring each other
Relatively strong amount of scientific and clinical research
Haploinsufficiency (like Dravet – STOKE) – so relatively easy
7. Expensive?
No. Clinical Research is more expensive than basic scientific research.
Leveraging CHOP and Rare-X, setting up required networks to prepare for clinical trials.
It’s time.
8. Why Bother/Help?
Now is the time for SYNGAP1, we miss it at our peril.
Sure, once in these places we will still see our patients, but the study, the support and the focus may pass.
Our kids don’t die, regardless of patient age, what we are doing can change their future and that of their loved ones and caregivers.
If not us, then who? It is a rare exception when a non-family member gives a gift, and it is always because a family member asked. We must ask.
9. What can I do?
Donate to, share, join our Coast2Coast Clinics Challenge – two SYNGAP1 Squads in West and East – it’s critical
$500k goal by end of 2024; more than $1M needed just for the SYNGAP1ProMMiS. So far, donations from $25 to $25,000 – each and every contribution matters.
This requires our entire S1 network to solicit family, friends, work colleagues, companies, etc. to contribute. Many causes out there – why not ours?
Syngap.Fund/C2C
https://Syngap.Fund/C2C > https://secure.givelively.org/donate/syngap-research-fund-incorporated/coast2coast-clinics-challenge
Two teams:
https://Syngap.Fund/West & https://Syngap.Fund/East
First Principles
Genetic disease means that gene broken since conception.
Novel medicines are possible ways to fix the gene - Genetic Therapies (ASO &/or AAV), this is recent, before now, kids with these diseases were a “go home and love them” situation.
These are delivered via spinal tap or directly to the brain in leading medical centers.
First though, regulators must approve.
Our job
Develop medicines or get industry to - This is happening see Pipeline
Get regulators to approve trials
Get medical centers up to speed on SYNGAP1-Related Disorders (SRD)
What we are building on
CHOP ENDD funded externally (see #S10e92) and replicating what was built for STXBP1, check last week’s webinar https://curesyngap1.org/resources/webinars/93-endd-chop-2024-syngap1/
Rare-X platform for PRO collection
Regulatory pathway being made clearer every day by Stoke (Dravet), Praxis (SCN2A), Ionis (many) all of whom are working on SYNGAP1 as well.
What we are asking for
We need to raise at least $500k (3rd site), preferably $1.13M (ProMMiS)
Make your largest gift ever to SRF
Fundraise with friends and family
ACES is now ProMMiS, who knew ACE meant Adverse Childhood Event, not us.
Key slides: S1 Path to Treatment | 2024 (09.27.24)
1. Why Now? Why is it time to go from bench to bedside (research to clinical)?
At least 10 companies on our pipeline not to mention multiple small molecule efforts
We have limited resources – so the focus has to transition, clinical funding first.
CHOP Gift is 1 year down…
2. Why NHS?Understand SYNGAP1 better, go beyond Vlaskamp 2019 and Wiltrout 2024, see #S10e105
FYI at CHOP, as I shared in #S10e151, at year 1, we are at – 86 (Visits) + 10 (new scheduled) + 19 (2nd) + 4 (3rd) + 22 (follow up)
Learn what to measure in clinical trials for SRD, remember our seizures are challenging
Ideally we develop a Synthetic Control Arm if we use GCP
Why top shelf? We need institutions the FDA will take seriously and our children are very complex requiring experienced clinicians.
3. Why Multidisciplinary.
Neuro, Psych, Genetics, PT, ST, OT, GI, Sleep, ENT, Ortho.
Beyond the sheer burden of getting our kids out and about for multiple appointments the coordination by a parent is almost impossible.
4. Why Multisite/3 sites?Replicable/scalable required by regulators
Accessibility (not primary reason)
Establish more locations where trials will be managed
Laying a foundation for a national self-sustaining network
3 is the minimum, look at STARR or Angelman, both had/ve 4.
5. How and why so fast?
Because we can. Time is Brain.
Following a well trodden path
SMA, Rett, Angelman, Dravet, but we are moving FASTER.
6. Does the industry really care?
We are next there are so so many behind us, eager to take the resources we have access to today.
Market size (Per our Census 425 US/1500 global is tip of iceberg)
Multiple players reassuring each other
Relatively strong amount of scientific and clinical research
Haploinsufficiency (like Dravet – STOKE) – so relatively easy
7. Expensive?
No. Clinical Research is more expensive than basic scientific research.
Leveraging CHOP and Rare-X, setting up required networks to prepare for clinical trials.
It’s time.
8. Why Bother/Help?
Now is the time for SYNGAP1, we miss it at our peril.
Sure, once in these places we will still see our patients, but the study, the support and the focus may pass.
Our kids don’t die, regardless of patient age, what we are doing can change their future and that of their loved ones and caregivers.
If not us, then who? It is a rare exception when a non-family member gives a gift, and it is always because a family member asked. We must ask.
9. What can I do?
Donate to, share, join our Coast2Coast Clinics Challenge – two SYNGAP1 Squads in West and East – it’s critical
$500k goal by end of 2024; more than $1M needed just for the SYNGAP1ProMMiS. So far, donations from $25 to $25,000 – each and every contribution matters.
This requires our entire S1 network to solicit family, friends, work colleagues, companies, etc. to contribute. Many causes out there – why not ours?
Syngap.Fund/C2C
https://Syngap.Fund/C2C > https://secure.givelively.org/donate/syngap-research-fund-incorporated/coast2coast-clinics-challenge
Two teams:
https://Syngap.Fund/West & https://Syngap.Fund/East
More episodes of the podcast SynGAP10 weekly 10 minute updates on SYNGAP1
DSC - RDCRN - NCATS - NIH Press! #AAV in #Cell. SRF at CB. Scramble for SYNGAP1 next week! #S10e184
26/09/2025
You need a #CRID. SRF $1M to $CAMP noticed in Equity Research! #BeaconOfHope was great. #S10e183
26/09/2025
CURE SYNGAP1 joins biotech investors in CAMP4 Tx’s $100M Raise for ASO Program $CAMP #S10e182
10/09/2025
Why & How Do Patient Advocacy Groups Matter? Party Friday! #SYNGAP1Conf soon! #Elopement #S10e181
08/09/2025
#IEP: Syngapians don’t like the heat 🌡️ #BeaconOfHope #IEC2025 #CitizenHealth #DSC #CFC #S10e180
29/08/2025
In God we trust